Physician profile
Webb R Mccanse
NPI 1770602930
$39,913.42
in general payments reported to CMS, 2019-2025
32 companies · $92.37 in 2025
The $92.37 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $8,721 · 2021: $22K · 2022: $4,594 · 2023: $4,385 · 2024: $217 · 2025: $92.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,035 · Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,035.06 |
| Food and Beverage | $659.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $37,939.77 | 2020-2023 | Da Vinci Surgical System |
| Boston Scientific Corporation | $390.51 | 2019-2023 | Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $200.20 | 2019-2025 | Xtandi |
| Palette Life Sciences, INC. | $153.89 | 2022 | |
| Amgen INC. | $113.57 | 2019-2022 | |
| Teleflex LLC | $98.12 | 2024 | Urolift |
| Procept Biorobotics Corporation | $88.25 | 2021 | |
| Axonics, INC. | $82.63 | 2023-2024 | Axonics |
| Dendreon Pharmaceuticals LLC | $81.37 | 2019-2024 | Provenge |
| Abbvie INC. | $80.14 | 2019-2021 | |
| Janssen Biotech, INC. | $71.14 | 2020 | |
| Laborie Medical Technologies Corp. | $62.96 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $55.17 | 2019-2023 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $43.49 | 2021-2024 | |
| Pfizer INC. | $43.48 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $43.47 | 2022-2024 | |
| Telix Pharmaceuticals | $40.43 | 2023 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Myriad Genetic Laboratories, INC. | $34.63 | 2023-2024 | Prolaris |
| Blue Earth Diagnostics | $34.55 | 2019 | |
| Antares Pharma, INC. | $32.69 | 2021-2024 | Xyosted |
| Baxter Healthcare | $25.82 | 2020 | |
| Tolmar, INC. | $20.55 | 2024 | |
| Accord Healthcare, INC. | $20.52 | 2025 | |
| Medtronic, INC. | $20.02 | 2022 | |
| Myovant Sciences INC. | $19.59 | 2021 | |
| Acerus Pharmaceuticals Corporation | $18.32 | 2021 | |
| Shionogi INC | $14.30 | 2021 | |
| Coloplast Corp | $13.01 | 2019 | |
| Allergan, INC. | $12.76 | 2020 | |
| Neotract INC. | $12.53 | 2020 | |
| Ambu INC. | $10.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Webb Mccanse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.